​

Exelixis (EXEL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

EXEL Stock Forecast

Exelixis (EXEL) stock forecast, based on 27 Wall Street analysts, predicts a 12-month average price target of $38.88, with a high of $42.00 and a low of $36.00. This represents a 7.55% increase from the last price of $36.15.

$20 $25 $30 $35 $40 $45 High: $42 Avg: $38.88 Low: $36 Last Closed Price: $36.15

EXEL Stock Rating

Exelixis stock's rating consensus is Buy, based on 27 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 17 Buy (62.96%), 10 Hold (37.04%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 27 0 10 17 Strong Sell Sell Hold Buy Strong Buy

EXEL Price Target Upside V Benchmarks

TypeNameUpside
StockExelixis7.55%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends

1M3M12M
# Anlaysts-223
Avg Price Target-$40.50$32.50
Last Closing Price$36.15$36.15$36.15
Upside/Downside-12.03%-10.10%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25479-121
Mar, 255710-123
Feb, 25588-122
Jan, 25599-124
Dec, 24598-224
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 13, 2025RBC Capital$40.00$36.808.70%10.65%
Jan 27, 2025Silvan TuerkcanJMP Securities$41.00$32.3826.62%13.42%
Jan 10, 2025Robert BurnsH.C. Wainwright$40.00$36.0211.05%10.65%
Jan 07, 2025Michael SchmidtGuggenheim$42.00$34.2122.77%16.18%
Oct 30, 2024Etzer DaroutBMO Capital$36.00$32.5610.57%-0.41%
Oct 30, 2024Asthika GoonewardeneTruist Financial$38.00$28.7332.27%5.12%
Oct 30, 2024Joseph CatanzaroPiper Sandler$36.00$28.7325.30%-0.41%
Oct 30, 2024David LebowitzCitigroup$38.00$28.7332.27%5.12%
Oct 16, 2024Christopher LiuLeerink Partners$28.50$28.50--21.16%
Oct 16, 2024Kennen MacKayRBC Capital$34.00$28.5019.30%-5.95%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 27, 2025JMP SecuritiesMarket OutperformMarket Outperformhold
Jan 23, 2025OppenheimerUnderperformPerformdowngrade
Jan 10, 2025H.C. WainwrightBuyBuyhold
Jan 09, 2025CitigroupBuyBuyhold
Jan 07, 2025GuggenheimBuyBuyhold
Dec 30, 2024RBC CapitalOutperformOutperformhold
Dec 19, 2024BMO CapitalOutperformMarket Performdowngrade
Oct 30, 2024GuggenheimBuyBuyhold
Oct 30, 2024Piper SandlerOverweightOverweighthold
Oct 21, 2024RBC CapitalUnderperformUnderperformhold

Financial Forecast

EPS Forecast

$0 $1 $2 $3 $4 $5 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.36$0.73$0.57$0.65$1.80----
Avg Forecast$0.32$0.48$0.56$0.62$1.73$1.91$2.31$2.95$3.70
High Forecast$0.34$0.51$0.61$0.67$1.87$2.23$3.03$4.31$4.14
Low Forecast$0.30$0.45$0.53$0.49$1.55$1.57$1.20$1.26$3.49
Surprise %12.50%52.08%1.79%4.84%4.05%----

Revenue Forecast

$500M $1B $2B $2B $3B $4B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$987.54M$1.43B$1.61B$1.83B$2.17B----
Avg Forecast$988.00M$1.34B$1.60B$1.83B$2.16B$2.23B$2.47B$2.76B$3.10B
High Forecast$1.04B$1.40B$1.71B$1.87B$2.17B$2.46B$2.48B$2.77B$3.38B
Low Forecast$944.85M$1.28B$1.52B$1.82B$2.15B$2.15B$2.46B$2.74B$2.96B
Surprise %-0.05%7.20%0.48%-0.08%0.19%----

Net Income Forecast

$-500M $-100M $300M $700M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$111.78M$231.06M$182.28M$207.76M$521.27M----
Avg Forecast$-224.71M$584.15M$677.63M$207.76M$549.48M$552.48M$682.27M$877.02M$1.19B
High Forecast$-131.24M$700.98M$813.16M$249.32M$600.20M$716.83M$974.37M$1.38B$1.33B
Low Forecast$-318.18M$467.32M$542.11M$166.21M$498.76M$504.33M$387.25M$406.53M$1.12B
Surprise %-149.74%-60.44%-73.10%--5.13%----

EXEL Forecast FAQ

Is Exelixis stock a buy?

Exelixis stock has a consensus rating of Buy, based on 27 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 17 Buy, 10 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Exelixis is a favorable investment for most analysts.

What is Exelixis's price target?

Exelixis's price target, set by 27 Wall Street analysts, averages $38.88 over the next 12 months. The price target range spans from $36 at the low end to $42 at the high end, suggesting a potential 7.55% change from the previous closing price of $36.15.

How does Exelixis stock forecast compare to its benchmarks?

Exelixis's stock forecast shows a 7.55% upside, underperforming the average forecast for the healthcare stocks sector (33.91%) and underperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for Exelixis over the past three months?

  • April 2025: 19.05% Strong Buy, 33.33% Buy, 42.86% Hold, 0% Sell, 4.76% Strong Sell.
  • March 2025: 21.74% Strong Buy, 30.43% Buy, 43.48% Hold, 0% Sell, 4.35% Strong Sell.
  • February 2025: 22.73% Strong Buy, 36.36% Buy, 36.36% Hold, 0% Sell, 4.55% Strong Sell.

What is Exelixis’s EPS forecast?

Exelixis's average annual EPS forecast for its fiscal year ending in December 2025 is $1.91, marking a 6.11% increase from the reported $1.8 in 2024. Estimates for the following years are $2.31 in 2026, $2.95 in 2027, and $3.7 in 2028.

What is Exelixis’s revenue forecast?

Exelixis's average annual revenue forecast for its fiscal year ending in December 2025 is $2.23B, reflecting a 3.00% increase from the reported $2.17B in 2024. The forecast for 2026 is $2.47B, followed by $2.76B for 2027, and $3.1B for 2028.

What is Exelixis’s net income forecast?

Exelixis's net income forecast for the fiscal year ending in December 2025 stands at $552.48M, representing an 5.99% increase from the reported $521.27M in 2024. Projections indicate $682.27M in 2026, $877.02M in 2027, and $1.19B in 2028.